FIELD OF APPLICATIONDETAILS
Generic Name
Lecanemab-irmb
Active Ingredient
Lecanemab-irmb
US Brand Names
Leqembi, Leqembi Iqlik
Drug Category
Alzheimer Disease Therapies
Drug Class
Amyloid Beta-Directed Antibody
Route of Administration
Intravenous Infusion, Subcutaneous Injection
FDA Approval Status
FDA approved in January 2023
Approved

Lecanemab-irmb Overview

Lecanemab-irmb is a prescription medication used to treat adults with early stage Alzheimer disease. Neurologists prescribe this targeted therapy to help clear harmful protein buildups in the brain, with the goal of slowing down memory loss and cognitive decline.

Key Facts Summary:

What Is Lecanemab-irmb and How Does It Work?

Lecanemab-irmb is a monoclonal antibody, which is a man-made protein designed to act like your body’s natural immune system.

Mechanism of Action

In Alzheimer disease, a normal brain protein called amyloid beta starts to fold incorrectly and stick together. Over time, these sticky proteins form large clumps called plaques between the brain cells. These plaques disrupt cell communication and cause brain cells to die, leading to memory loss.

Lecanemab-irmb works by specifically finding and attaching to these sticky amyloid proteins before they can form large, hard plaques. Once the drug attaches to the amyloid, it acts like a flag that signals your body’s immune system to come and clean the harmful proteins away. By clearing these proteins, the medicine helps protect the remaining brain cells.

Is Lecanemab-irmb FDA Approved?

Yes, Lecanemab-irmb is officially approved by the United States Food and Drug Administration. It is one of the first treatments proven to treat the underlying biology of Alzheimer disease, rather than just treating the symptoms.

What Is Lecanemab-irmb Used For?

  • Treatment of Alzheimer disease in patients with mild cognitive impairment or mild dementia stage of disease.
  • Limitations of Use: Patients must have a doctor confirm the presence of amyloid beta in their brain before starting treatment. There is no safety or effectiveness data for initiating treatment at earlier or later stages of the disease.

Before Taking Lecanemab-irmb: Contraindications and Precautions

Because this medication works inside the brain, your doctor will require brain scans (MRIs) and genetic blood tests to ensure you can safely receive this treatment.

Who Should Not Take Lecanemab-irmb?

  • Anyone with a known severe hypersensitivity or allergic reaction to Lecanemab-irmb or any of its inactive ingredients.
  • Patients who cannot undergo routine MRI scans (for example, those with certain pacemakers or metallic implants).

Lecanemab-irmb, Pregnancy and Fertility

Alzheimer disease primarily affects older adults, so there is no data on the use of Lecanemab-irmb in pregnant women. It is unknown if Lecanemab-irmb passes into human breast milk.

Tell Your Doctor Before Taking Lecanemab-irmb

  • Disclose if you take any blood thinners (anticoagulants) or have a history of bleeding disorders.
  • Inform your provider if you have had a recent stroke, mini-stroke (TIA), or seizures.
  • Share if you have a history of heart problems or uncontrolled high blood pressure.
  • Inform your doctor if you know your APOE gene status (specifically if you carry the APOE epsilon 4 gene), as this drastically changes your risk for side effects.

Lecanemab-irmb Dosage and Administration

Lecanemab-irmb is administered primarily as an intravenous (IV) infusion. A subcutaneous (under the skin) injection form is also available for maintenance treatment.

Standard Lecanemab-irmb Dosing

  • Recommended Dose: 10 milligrams per kilogram of body weight (10 mg/kg).
  • Schedule: Administered once every two weeks.
  • Maintenance Option: Patients who have completed at least 26 weeks of IV therapy and do not have severe side effects may switch to a weekly subcutaneous maintenance injection, as directed by their doctor.

How Lecanemab-irmb Is Administered

  • IV infusions are given by a healthcare professional in a hospital or clinic and take about 1 hour to complete.
  • You will be monitored for at least 3 hours after your very first infusion to check for allergic reactions.
  • If you switch to the subcutaneous injection form, a healthcare provider will show you or your caregiver how to inject it into your stomach or thigh at home.

Lecanemab-irmb Clinical Efficacy and Research

The FDA approval was based on an 18-month clinical trial involving almost 1,800 patients with early Alzheimer disease. Patients receiving Lecanemab-irmb showed a significant reduction in brain amyloid plaques compared to patients receiving a placebo. More importantly, clinical memory and functional tests showed that patients taking the drug experienced a 27 percent slower rate of cognitive decline. While this means the drug does not stop or reverse the disease, it successfully gives patients more time with higher mental function and independence.

Lecanemab-irmb Side Effects and Safety Profile

BLACK BOX WARNING

If you experience a mild headache or chills during the infusion, your nurse can slow down the drip or provide medications like acetaminophen to help. If you experience severe headaches, sudden confusion, difficulty walking, or changes in your vision at any point at home, contact your doctor or go to the emergency room immediately, as these are signs of severe brain swelling or bleeding.

Clearing amyloid from the brain can cause the tiny blood vessels in the brain to become temporarily leaky, leading to a serious condition called ARIA.

  • BOXED WARNING (Amyloid Related Imaging Abnormalities – ARIA): Monoclonal antibodies targeting amyloid beta, including Lecanemab-irmb, can cause Amyloid Related Imaging Abnormalities (ARIA), which can present as ARIA with edema (ARIA-E, brain swelling) and ARIA with hemosiderin deposition (ARIA-H, brain microhemorrhages and superficial siderosis). While ARIA is often asymptomatic, serious and life-threatening events, including brain edema, larger brain hemorrhages, and fatal outcomes, have occurred. The risk of ARIA is significantly increased in patients who are APOE ε4 homozygotes. Testing for APOE ε4 status should be performed prior to initiating treatment to inform patient risk assessment and discussion.

Common Lecanemab-irmb Side Effects

  • Infusion-related reactions (chills, body aches, nausea).
  • Headache.
  • Brain swelling (ARIA-E) seen on an MRI.
  • Tiny brain bleeds (ARIA-H) seen on an MRI.
  • Cough or runny nose.

Serious Lecanemab-irmb Adverse Events

  • Amyloid Related Imaging Abnormalities (ARIA): Severe brain swelling causing confusion, severe headache, dizziness, gait disturbance, or vision changes.
  • Intracerebral Hemorrhage: Larger strokes or severe brain bleeding, especially in patients taking concurrent blood thinners.
  • Infusion/Hypersensitivity Reactions: Severe allergic reactions occurring during or shortly after the infusion, causing fever, chills, low blood pressure, and difficulty breathing (anaphylaxis).

Managing Lecanemab-irmb Side Effects

Lecanemab-irmb Drug Interactions and What to Avoid

Because of the risk of brain bleeding, you must be extremely careful with medications that affect how your blood clots.

Lecanemab-irmb Drug-Drug Interactions

  • Anticoagulants (Blood Thinners like Warfarin, Eliquis, Xarelto): Taking these medications with Lecanemab-irmb significantly increases your risk of severe and potentially fatal brain bleeding. Discuss the risks carefully with your doctor.
  • Thrombolytics (Clot-busting drugs like tPA): If you suffer a stroke while taking Lecanemab-irmb, emergency doctors must be extremely cautious about using clot-busting drugs due to an exceptionally high risk of massive brain bleeding.

Lecanemab-irmb, Food and Alcohol

  • There are no known food interactions with this medication.
  • Avoid heavy alcohol use, as it can increase your risk of falling, which could lead to head trauma and brain bleeding.

Lecanemab-irmb Missed Dose, Overdose and Storage

Keeping your biweekly infusion appointments is critical for safely clearing the amyloid plaques.

Missed Dose of Lecanemab-irmb

If you miss an infusion appointment, contact your treatment center immediately to reschedule. If you miss multiple doses, your doctor will advise you on how to safely restart the treatment.

Lecanemab-irmb Overdose and Emergency

Because this medication is administered by a healthcare professional based on your exact weight, an overdose is unlikely. If you suspect an error in your dose, alert the medical staff immediately for monitoring.

How to Store Lecanemab-irmb

  • The glass vials must be stored in the refrigerator between 36°F and 46°F (2°C and 8°C) by the pharmacy or clinic.
  • If you are prescribed the at-home subcutaneous autoinjector, store it in the refrigerator in its original carton to protect it from light. Do not freeze it.

Lecanemab-irmb Patient Management and Monitoring

Your doctor will strictly monitor your brain health using MRI scans to ensure ARIA (brain swelling or bleeding) is not developing silently.

Tests Before Starting Lecanemab-irmb

  • A PET scan or spinal tap to confirm you actually have amyloid plaques in your brain.
  • A baseline MRI scan of your brain (within 1 year of starting).
  • Blood test to check your APOE epsilon 4 genetic status.

Monitoring During Lecanemab-irmb Treatment

  • Mandatory MRI scans are required before your 5th, 7th, and 14th infusions to check for ARIA.
  • If ARIA is detected on an MRI, your doctor may pause your treatment until the swelling goes away.
  • Ongoing monitoring for memory changes and infusion reactions.

Lecanemab-irmb Do’s and Don’ts

  • DO carry a medical alert card stating you are receiving an amyloid-targeting antibody, in case of an emergency stroke.
  • DO attend all of your scheduled MRI appointments; you cannot receive your next dose without them.
  • DON’T start taking any new blood thinners or daily aspirin without talking to your neurologist first.
  • DON’T ignore severe headaches, vision changes, or sudden confusion.

Frequently Asked Questions

What is this medicine used for?

It is a prescription intravenous (IV) therapy used to treat patients in the early stages of Alzheimer disease (mild cognitive impairment or mild dementia).

Does Lecanemab-irmb cure Alzheimer disease?

No, it is not a cure. It removes amyloid plaques from the brain, which has been shown to slow down the rate at which memory and thinking skills decline, but it does not reverse the disease.

What is ARIA?

ARIA stands for Amyloid Related Imaging Abnormalities. It is a side effect seen on MRI scans that indicates swelling or tiny bleeding spots in the brain. It often causes no symptoms, but can sometimes be severe or life-threatening.

Why do I need a genetic test before starting?

Patients who inherit two copies of a specific gene called APOE epsilon 4 have a much higher risk of developing severe ARIA (brain swelling and bleeding). Knowing your gene status helps you and your doctor make an informed decision about safety.

How often do I need to get brain scans?

You will need a baseline MRI before starting, and then routine safety MRIs before your 5th, 7th, and 14th infusions (roughly at 2, 3, and 6 months of treatment).

Can I take this if I have late-stage Alzheimer disease?

No. This medicine has only been studied and approved for patients in the early stages of the disease.

References

  • U.S. FDA prescribing information for Leqembi (Lecanemab-irmb)
  • U.S. FDA Drugs@FDA drug approval overview (Application No. 761375)
  • Alzheimer’s Association Guidelines on Anti-Amyloid Therapies
  • Clinical Pharmacology Review of Amyloid Beta-Directed Monoclonal Antibodies

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.